J.P. Morgan Securities LLC Xeris Pharmaceuticals Inc Amnd 8.3 (7369D)
30 Junio 2021 - 11:46AM
UK Regulatory
TIDM0A8E
RNS Number : 7369D
J.P. Morgan Securities LLC
30 June 2021
Ap19
AMENDMENT
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing J.P. Morgan Securities
(Note 1) LLC
Company dealt in Xeris Pharmaceuticals,
Inc.
======================
Class of relevant security $0.001 common stock
to which the dealings
being disclosed relate
(Note 2)
======================
Date of dealing 25 June 2021
======================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities 3,358,325 5.06 745,699 1.12
----------------- -------------------
(2) Derivatives (other
than options) 263,078 0.40
----------------- -------------------
(3) Options and agreements
to purchase/sell
----------------- -------------------
Total 3,621,403 5.46 745,699 1.12
----------------- -------------------
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(USD)
(Note 5)
Purchase(Loan 22,000 N/A
Return)
100 4.9600 USD
Purchases 105 4.8600 USD
Purchases 35,100 4.8103 USD
Purchases 31,936 4.8100 USD
Purchases 100 4.7950 USD
Purchases 68 4.7900 USD
Purchases 3,315 4.7751 USD
Purchases 603 4.7747 USD
Purchases 1,960 4.7478 USD
Purchases 200 4.7450 USD
Purchases 409 4.7402 USD
Purchases 32,395 4.7273 USD
Purchases 166 4.7200 USD
Purchases 1,071 4.7065 USD
Purchases 62,906 4.6958 USD
Purchases 2,394 4.6704 USD
Purchases 300 4.6544 USD
Purchases 11,391 4.6464 USD
Purchases 2,464 4.6321 USD
Purchases 100 4.6304 USD
Purchases 1,453 4.6300 USD
Purchases 6,963 4.6022 USD
Purchases 100 4.5100 USD
Purchases 100 4.4600 USD
Purchases 201 4.4533 USD
Purchases 100 4.3900 USD
Purchases
54,893 4.8100 USD
Sales 1,071 4.7065 USD
Sales 62,906 4.6958 USD
Sales 344 4.6400 USD
Sales 100 4.6000 USD
Sales 300 4.5600 USD
Sales 245 4.5500 USD
Sales 201 4.4533 USD
Sales 101 4.3800 USD
Sales
====================================== ====================
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per
e.g. CFD (Note 6) securities unit
(Note 7) (USD) (Note
5)
Equity Swap Decrease Long 62,906 4.6959 USD
1,071 4.7065 USD
===================== ================== =============
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and
any other person relating to the voting rights of any relevant
securities under any option referred to
on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to
which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 30 June 2021
Contact name Alwyn Basch
=============
Telephone number 0207 742 7407
=============
If a connected EFM, name N/A
of offeree/offeror with
which connected
=============
If a connected EFM, state N/A
nature of connection (Note
10)
=============
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEURSNRAVUNOAR
(END) Dow Jones Newswires
June 30, 2021 12:46 ET (16:46 GMT)
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De May 2023 a May 2024
